Volume 68, Issue 6

Search all Cancer Chemotherapy and Pharmacology articles

December 2011

32 articles in this issue

Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB
Xian-Hua Fu
Jun Li
Su-Zhan Zhang
Mini Review 23 September 2011 Pages: 1373 - 1376
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors
Patricia LoRusso
Geoffrey I. Shapiro
Eric Masson
Original Article 03 April 2011 Pages: 1377 - 1385
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
Sung-Hsin Kuo
Ann-Lii Cheng
Li-Tzong Chen
Original Article 05 April 2011 Pages: 1387 - 1395
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
P. Schöffski
H. Dumez
G. Giaccone
Original Article 05 April 2011 Pages: 1397 - 1403
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation
Giulio Metro
R. Chiari
L. Crinò
Original Article 06 April 2011 Pages: 1405 - 1412
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
N. Frances
L. Claret
A. Iliadis
Original Article 08 April 2011 Pages: 1413 - 1419
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway
Shuang-Jia Wang
Bei Sun
Xue-Wei Bai
Original Article 09 April 2011 Pages: 1421 - 1430
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
David Fogelman
Mehrdad Jafari
Robert A. Wolff
Original Article 09 April 2011 Pages: 1431 - 1438
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B. Leal
Scot C. Remick
Daniel Mulkerin
Original Article 09 April 2011 Pages: 1439 - 1447
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation
Cristina P. R. Xavier
Cristovao F. Lima
Cristina Pereira-Wilson
Original Article 11 April 2011 Pages: 1449 - 1457
Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment
My Björklund
Jeanette Roos
Maria Shoshan
Original Article 11 April 2011 Pages: 1459 - 1467
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma
Robin E. Norris
Jane E. Minturn
Peter C. Adamson
Original Article 12 April 2011 Pages: 1469 - 1475
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study
Peter Mu-Hsin Chang
Cheng-Hwai Tzeng
Muh-Hwa Yang
Original Article 12 April 2011 Pages: 1477 - 1484
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
Jiri Horak
Jeff White
Chris Twelves
Original Article 13 April 2011 Pages: 1485 - 1495
Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer
Fatma Sen
Esra Kaytan Saglam
Adnan Aydiner
Original Article 17 April 2011 Pages: 1497 - 1505
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
Apostolia-Maria Tsimberidou
Nancy Lewis
Razelle Kurzrock
Original Article 17 April 2011 Pages: 1507 - 1516
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor
Elena Soto
Alexander Staab
Iñaki F. Trocóniz
Original Article 24 April 2011 Pages: 1517 - 1527
Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients
Keyvan Rezai
S. Urien
F. Lokiec
Original Article 26 April 2011 Pages: 1529 - 1536
Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
Rebecca G. Bagley
Leslie Kurtzberg
Beverly A. Teicher
Original Article 28 April 2011 Pages: 1537 - 1546
Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model
Cecilia Engmér Berglin
Pernilla Videhult Pierre
Göran Laurell
Original Article 02 May 2011 Pages: 1547 - 1556
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
Ario Takeuchi
Masaki Shiota
Seiji Naito
Original Article 05 May 2011 Pages: 1557 - 1564
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
Muhammad Wasif Saif
John Sarantopoulos
Murali Beeram
Original Article 06 May 2011 Pages: 1565 - 1573
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials
Daniel Binder
Ralf-Harto Hübner
Peter Schlattmann
Original Article 06 May 2011 Pages: 1575 - 1583
Preclinical evaluation of the novel multi-targeted agent R1530
Kenneth Kolinsky
Christian Tovar
Brian Higgins
Original Article 08 May 2011 Pages: 1585 - 1594
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202
Syma Iqbal
Cathryn Rankin
Charles D. Blanke
Original Article 10 May 2011 Pages: 1595 - 1602
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy
Tomomi Egawa-Takata
Yutaka Ueda
Takayuki Enomoto
Original Article 17 May 2011 Pages: 1603 - 1610
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
Maurice C. van Staveren
Barbara Theeuwes-Oonk
Jan Gerard Maring
Original Article Open access 18 May 2011 Pages: 1611 - 1617
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen
Patricia M. M. B. Soetekouw
Mark Middleton
Clinical Trial Report Open access 28 September 2011 Pages: 1619 - 1628
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
Jacqueline Ramírez
Kehua Wu
Mark J. Ratain
Short Communication 23 August 2011 Pages: 1629 - 1632
Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
Romain Guilhaumou
Caroline Solas
Nicolas Andre
Short Communication 04 October 2011 Pages: 1633 - 1638
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Fabio Farinati
Anna Giacomin
Veronica Vanin
Letter to the Editor 10 November 2011 Pages: 1639 - 1640
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Jeong Eun Kim
Baek-Yeol Ryoo
Yoon-Koo Kang
reply 09 November 2011 Pages: 1641 - 1642

Volume 68, Issue 6

Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB

Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors

t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement

Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation

Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation

Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment

Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma

Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer

Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer

Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients

Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells

Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model

Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors

Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials

Preclinical evaluation of the novel multi-targeted agent R1530

A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202

Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy

Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients

Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

Navigation